BioCentury | Oct 12, 2015
Clinical News

Bamosiran: Phase II data

...and a baseline IOP of >=23 mmHg showed that once-daily 0.375%, 0.75%, 1.125% and 1.5% bamosiran...
...twice-daily 0.5% timolol in reducing IOP from baseline to day 28. The 1.125% dose of bamosiran...
...subsidiary of Zeltia S.A. (Madrid:ZEL, Madrid, Spain). Sylentis S.A. , Madrid, Spain Product: Bamosiran ( SYL040012...
BioCentury | Jun 10, 2013
Clinical News

SYL040012: Phase IIa data

...after "all of the trial's variables have been analyzed." Sylentis S.A. , Madrid, Spain Product: SYL040012...
BioCentury | Jun 18, 2012
Clinical News

SYL040012: Phase II started

...Sylentis said it began a placebo-controlled, dose-ranging, European Phase II trial to evaluate daily SYL040012 eye...
...is a subsidiary of Zeltia S.A. (Madrid:ZEL, Madrid, Spain). Sylentis S.A. , Madrid, Spain Product: SYL040012...
BioCentury | Dec 6, 2010
Clinical News

SYL040012: Phase I/II started

...Zeltia's Sylentis S.A. subsidiary began an open-label, Spanish Phase I/II trial to evaluate SYL040012 ophthalmic drops...
...administered once daily for 7 days in 30 patients. Zeltia S.A. (Madrid:ZEL), Madrid, Spain Product: SYL040012...
BioCentury | Sep 13, 2010
Clinical News

SYL040012: Phase I/II start

...SYL040012 ophthalmic drops given once daily in 30 patients. Zeltia S.A. (Madrid:ZEL), Madrid, Spain Product: SYL040012...
BioCentury | Jul 19, 2010
Clinical News

SYL040012: Phase Ia data

...single-blind, Spanish Phase Ia trial showing that subjects displayed "excellent" local and systemic tolerance to SYL040012...
...to start Phase I/II testing as soon as possible. Zeltia S.A. (Madrid:ZEL), Madrid, Spain Product: SYL040012...
BioCentury | Jun 1, 2009
Clinical News

Zeltia preclinical data

...In a rabbit model of hypertension, SYL040012 prevented intraocular pressure increase and ocular hypertension induced by...
...Research in Vision and Ophthalmology meeting in Fort Lauderdale. Zeltia S.A. (Madrid:ZEL), Madrid, Spain Product: SYL040012...
Items per page:
1 - 7 of 7